ClinicalTrials.gov
public full text
Public Domain
NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment#826450
- Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy#835949
- An Extension Study of V203-AD Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UB-311#1087242
- Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients#234477
- Venetoclax and Blinatumomab for adult patients with relapsed/refractory or MRD positive Ph-negative B-cell precursor ALL: phase I part of the GMALL-BLIVEN trial#1079139
Record · ID 249580
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive